Friday Avalo Therapeutics Reported FY2023 EPS $(114.00) Misses $(96.00) Estimate, Sales $1.92M Beat $1.70M Estimate
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics reported its FY2023 earnings with an EPS of $(114.00), missing the $(96.00) estimate. However, its sales of $1.92M exceeded the $1.70M estimate.
April 01, 2024 | 10:20 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avalo Therapeutics reported a larger-than-expected loss per share but exceeded sales estimates for FY2023.
The miss on the EPS estimate is likely to negatively impact investor sentiment in the short term, despite the sales beat. Typically, earnings misses can lead to a decrease in stock price as they may indicate underlying issues not apparent in revenue figures alone.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100